Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Q3 2025 Earnings Call November 10, 2025 5:00 PM ESTCompany ParticipantsRick Winningham - CEO & DirectorRhonda Farnum ...

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...

With just a day to its Ibadan convention, the Peoples Democratic Party (PDP) is trapped in a storm of conflicting court ...

Retired Ministry of Natural Resources manager Alan Bisset attended a conference on moose management held in Sweden recently ...

Never bet against tech Part 3 of a 4-part series Now semi-retired Alaska economist Gunnar Knapp, the nation’s foremost authority on the economics of the Alaska fishing business, offered a ...

Corey and Christine will provide an update on the commercial launch of Orlynda in the U.S. Corey will also give an update on ...

International meetings offer researchers worldwide the chance to explore the cutting edge of science, generate new ideas, and ...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Be ...

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral ...

Ruvidar and Rutherrin show strong potential in treating bladder cancer, solid tumors, and HSV-1—including drug-resistant ...

Hormone therapy drugs have carried box warning labels for years. Food and Drug Administration Commissioner Marty Makary talks with NPR about why the agency is removing them.